532523 Stock Overview
Engages in the manufacture and sale of biotechnology products and research services in India, Brazil, Singapore, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 4/6 |
| Past Performance | 2/6 |
| Financial Health | 2/6 |
| Dividends | 2/6 |
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
Biocon Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₹330.65 |
| 52 Week High | ₹404.60 |
| 52 Week Low | ₹270.00 |
| Beta | 0.25 |
| 1 Month Change | 1.30% |
| 3 Month Change | 2.67% |
| 1 Year Change | 3.55% |
| 3 Year Change | -0.78% |
| 5 Year Change | -6.78% |
| Change since IPO | 719.20% |
Recent News & Updates
Recent updates
Shareholder Returns
| 532523 | IN Biotechs | IN Market | |
|---|---|---|---|
| 7D | -2.6% | -2.3% | -0.2% |
| 1Y | 3.6% | 9.0% | 2.2% |
Return vs Industry: 532523 underperformed the Indian Biotechs industry which returned 9% over the past year.
Return vs Market: 532523 exceeded the Indian Market which returned 2.2% over the past year.
Price Volatility
| 532523 volatility | |
|---|---|
| 532523 Average Weekly Movement | 5.4% |
| Biotechs Industry Average Movement | 7.4% |
| Market Average Movement | 7.0% |
| 10% most volatile stocks in IN Market | 9.6% |
| 10% least volatile stocks in IN Market | 4.7% |
Stable Share Price: 532523 has not had significant price volatility in the past 3 months compared to the Indian market.
Volatility Over Time: 532523's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1978 | 16,315 | Siddharth Mittal | www.biocon.com |
Biocon Limited, together with its subsidiaries, engages in the manufacture and sale of biotechnology products and research services in India, Brazil, Singapore, and internationally. It operates through four segments: Generics, Novel Biologics, Biosimilars, and Research Services. The company offers generic formulations and API products, including anti-diabetics, immunosuppressants, multiple sclerosis, anti-cancer/oncology, and other products; novel biologics products, such as head and neck cancer molecule; novel pipeline products comprising psoriasis molecules; and biosimilars products consisting of insulins, trastuzumab, pegfilgrastim, and bevacizumab.
Biocon Limited Fundamentals Summary
| 532523 fundamental statistics | |
|---|---|
| Market cap | ₹395.84b |
| Earnings (TTM) | ₹10.13b |
| Revenue (TTM) | ₹152.62b |
Is 532523 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 532523 income statement (TTM) | |
|---|---|
| Revenue | ₹152.62b |
| Cost of Revenue | ₹51.98b |
| Gross Profit | ₹100.64b |
| Other Expenses | ₹90.51b |
| Earnings | ₹10.13b |
Last Reported Earnings
Mar 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | 8.47 |
| Gross Margin | 65.94% |
| Net Profit Margin | 6.64% |
| Debt/Equity Ratio | 64.1% |
How did 532523 perform over the long term?
See historical performance and comparisonDividends
Does 532523 pay a reliable dividends?
See 532523 dividend history and benchmarks| Biocon dividend dates | |
|---|---|
| Ex Dividend Date | Jul 04 2025 |
| Dividend Pay Date | Sep 05 2025 |
| Days until Ex dividend | 40 days |
| Days until Dividend pay date | 103 days |
Does 532523 pay a reliable dividends?
See 532523 dividend history and benchmarksCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/24 00:51 |
| End of Day Share Price | 2025/05/23 00:00 |
| Earnings | 2025/03/31 |
| Annual Earnings | 2025/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Biocon Limited is covered by 45 analysts. 18 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Meeta Shetty | Asian Markets Securities Private Limited |
| Harith Ahamed | Avendus Spark |
| Kunal Randeria | Axis Capital Limited |